Search clinical trials for: Anti-CTLA4 (monoclonal antibody MDX-010)

Total 1523 results

Shanghai Henlius Biotech

Recruiting

A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer

Gastric Cancer

China
LigaChem Biosciences, Inc.
AntibodyChem Biosciences, Inc.

Recruiting

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Advanced Solid Tumors

United States, Canada
Taizhou Hanzhong biomedical co. LTD

Active, not recruiting

Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors

Advanced Solid Tumor

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer

Colorectal Cancer

United States, Australia
National Cancer Institute (NCI)

Completed

Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

Recurrent Breast Carcinoma | Invasive Breast Carcinoma | HER2/Neu Positive | Stage IV Breast Cancer AJCC v6 and v7

United States
Bristol-Myers Squibb

Completed

A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease

Hodgkin's Disease

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Hydronephrosis | Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage III Renal Pelvis Cancer AJCC v7 | Stage III Ureter Cancer AJCC v7 | Stage III Urethral Cancer AJCC v7 | Stage IV Renal Pelvis Cancer AJCC v7 | Stage IV... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8

United States, Canada
Institute of Hematology & Blood Diseases Hospital...
Henan Cancer Hospital; Beijing Children's Hospital; Tianjin Medical University... and other collaborators

Recruiting

TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)

Primary Immune Thrombocytopenia (ITP)

China
M.D. Anderson Cancer Center

Active, not recruiting

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study

Locally Advanced Angiosarcoma | Metastatic Angiosarcoma | Recurrent Angiosarcoma

United States
Medical University of Graz

Completed

Effects of Infliximab on Insulin Sensitivity and Beta Cell Function in Insulin Resistant Human Obesity

Obesity | Metabolic Syndrome | Insulin Resistance

Austria
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Recruiting

Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA

Non-radiographic Axial Spondyloarthritis

China
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)

Peripheral T Cell Lymphoma

China
Humanigen, Inc.

Terminated

Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast Cancer

Breast Cancer

United States
Cancer Institute and Hospital, Chinese Academy...
Peking University Cancer Hospital & Institute; Affiliated Cancer Hospital &... and other collaborators

Recruiting

Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL

Early-stage | Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type

China
Fudan University

Recruiting

Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy

Oropharyngeal Carcinoma

China
Sinocelltech Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Unknown

Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC

Metastatic Colorectal Cancer

China
Sinocelltech Ltd.

Completed

Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.

B-cell Non Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Colorectal Cancer Metastatic to the Liver

Colorectal Cancer | Metastatic Cancer

United States
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Prostate Cancer

United States
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects

COVID-19; and High Infection Risk of SARS-CoV-2

China
Humanigen, Inc.

Completed

Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids (KB003-04)

Moderate-to-Severe Asthma

France, United Kingdom, United States, Australia, Poland, Ukraine
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditions

United States
National Cancer Institute (NCI)

Completed

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IV Renal Cell Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Metastatic Squamous Neck Cancer With... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

Progressive Disease | Recurrent Colorectal Carcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer... and other conditions

United States
United BioPharma

Not yet recruiting

Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria

Chronic Idiopathic Urticaria
Johns Hopkins University
Massachusetts General Hospital; National Institutes of Health (NIH); National...

Terminated

Dietary Interventions in Asthma Treatment: Sprouts Study

Asthma | Allergy

United States
University of California, San Francisco
Gilead Sciences

Suspended

Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors (PNOC025)

Brain Cancer | Malignant Brain Tumor | Brain Tumor Adult | Recurrent Brain Tumor | Progressive Malignant Brain Tumor | Brain Tumor, Pediatric

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Recruiting

A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.

Gout Arthritis

China
National Cancer Institute (NCI)

Completed

Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery

Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer

United States
Nanjing Leads Biolabs Co.,Ltd

Recruiting

Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors

Advanced Malignant Tumors

China
Jacobio Pharmaceuticals Co., Ltd.
Merck Sharp & Dohme LLC

Recruiting

JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Solid Tumor

China
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Young Patients With Refractory Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma

United States
Energenx Medical LTD.

Recruiting

Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer

NSCLC

China
Chen Xiaoping

Completed

Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling

Hepatocellular Carcinoma | Checkpoint Inhibitor | Adjuvant Immunotherapy

China
Merck KGaA, Darmstadt, Germany

Terminated

TRUST Study: Raptiva ® in Hand & Foot Psoriasis (TRUST)

Chronic Plaque Psoriasis

Austria
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy

Breast Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific
Shi Yuankai

Unknown

SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma
University of Texas Southwestern Medical Center
Gateway for Cancer Research; Celldex Therapeutics

Recruiting

CD40 Agonist, Flt3 Ligand, and Chemotherapy in Triple Negative Breast Cancer

Metastatic Triple Negative Breast Cancer

United States
Great Ormond Street Hospital for Children NHS Foundation...

Recruiting

90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia (RITII)

Leukemia

United Kingdom
Biogen

Completed

BIIB033 In Acute Optic Neuritis (AON)

Acute Optic Neuritis

Sweden, Australia, Italy, Spain, United Kingdom, Germany, Belgium, Denmark, Hungary, Czech Republic, Canada
Robert L. Ferris, MD, PhD
Bristol-Myers Squibb

Recruiting

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States

Search clinical trials for: Anti-CTLA4 (monoclonal antibody MDX-010)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations